InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,540.59
(
1.92%
)
US TECH 100
18,818.40
(
2.83%
)
Dow Jones
41,130.40
(
0.95%
)
Brent Oil
80.95
(
3.03%
)
Bitcoin
66,509.98
(
0.51%
)
Post# of 252753
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 834
Posts 120168
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: Doc328 post# 244598

Wednesday, 12/28/2022 3:12:54 PM

Wednesday, December 28, 2022 3:12:54 PM

Post# of 252753
FDA approves TGTX’s Briumvi—(ublituximab)—for RMS:

https://finance.yahoo.com/news/tg-therapeutics-announces-fda-approval-184800130.html

Briumvi’s claim to fame is its dosing schedule: a 1-hour every 24 weeks, after the loading-dose regimen of a 4-hour infusion and a 1-hour infusion two weeks later.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up